Denise
Faltischek, Aphria's Chief Strategy Officer, and Tenured
Consumer Packaged Goods Executive to Lead German Operations
Aphria Remains On-Track to be the First
Licensed Producer to Cultivate Medical Cannabis in
Germany
LEAMINGTON, ON, Feb. 8, 2021 /PRNewswire/ - Aphria Inc.
("Aphria," "we," or the "Company") (TSX:
APHA) and (NASDAQ: APHA), a leading global cannabis-lifestyle
consumer packaged goods company inspiring and empowering the
worldwide community to live their best life, today announced
Denise Faltischek, Aphria's Chief
Strategy Officer, will also assume the role of Managing Director of
Aphria Germany, effective January 23,
2021, reporting to Irwin D.
Simon, Aphria's Chairman and Chief Executive Officer.
Ms. Faltischek joined Aphria in September 2019 with extensive consumer-packaged
goods experience and expertise leading over 50 acquisitions. She
leads Aphria's global business strategy and oversees Aphria's
medical and international business segments as well as quality
function.
Irwin D. Simon commented, "Denise
has been instrumental in leading our strategic initiatives in
Canada and internationally as
we've scaled our operations. We are excited for her to further
expand her role by also leading our day-to-day operations in
Germany where she has worked
closely with the team since joining Aphria. In Germany, we are leveraging our strong medical
platform and our multifaceted international operation, which
combines in-country cultivation, import permits and large
distribution infrastructure to increase access and availability to
high-quality, consistent medical cannabis for patients. In
establishing our international footprint in Germany, we invested in the completion of our
in-country cultivation facility and distribution network in
Neumünster, Germany."
Mr. Simon, continued, "In Europe, upon the closing of our
business combination with Tilray, we will enhance our footprint
with five strong brands to help us establish an unrivaled European
platform, including two production facilities and a robust and
flexible supply chain given Tilray's EU-GMP facility in
Portugal. Tilray has a leading
medical cannabis operation in Europe that will benefit our existing medical
sales and distribution as well as extend CC Pharma's medical
cannabis offering with access to over 13,000 pharmacies in
Germany."
Aphria remains on-track to be the first licensed producer to
cultivate medical cannabis in Germany with the opening of its cultivation
facility in Neumünster, Germany,
which is awaiting EU-GMP certification. It is expected that
the first harvest will occur in the first quarter of calendar year
2021.
"We believe the European Union continues to have many robust
growth opportunities for Aphria and Germany represents the most sought-after
market within those countries," commented Ms. Faltischek. "We've
recently achieved several significant milestones in Germany that strengthen our position as a
leading cannabis company in the European Union, including the
completion of our first certified EU-GMP shipment of dried flower
from our Canadian Aphria One facility to our German subsidiary, CC
Pharma, as well as the introduction of Aphria Strong 9, our first
THC-dominant medical cannabis flower. We also recently
completed our first shipment of certified EU-GMP medical cannabis
oils for the German market. Going forward, we remain well
positioned for long-term growth in Germany and Europe."
We Have A Good Thing Growing
About Aphria Inc.
Aphria Inc. is a leading global cannabis-lifestyle consumer
packaged goods company with operations in Canada, United
States, Europe and
Latin America, that is changing
people's lives for the better – one person at a time – by inspiring
and empowering the worldwide community to live their very best life
by providing them with products that meet the needs of their mind,
body and soul and invoke a sense of wellbeing. Aphria's mission is
to be the trusted partner for its patients and consumers by
providing them with a cultivated experience and health and
wellbeing through high-quality, differentiated brands and
innovative products. Headquartered in Leamington, Ontario, Aphria cultivates,
processes, markets and sells medical and adult-use cannabis,
cannabis-derived extracts and derivative cannabis products in
Canada under the provisions of the
Cannabis Act and globally pursuant to applicable international
regulations. Aphria also manufactures, markets and sells alcoholic
beverages in the United
States.
For more information, visit: aphriainc.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws and are expressly
qualified by this cautionary statement. Any statements that are
contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to Aphria's expected supply
of product in international jurisdictions, and the launch of
branded product offerings. Forward-looking statements are based on
the opinions, estimates and perception of trends of management and
its beliefs with respect to future events, as at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. Factors that may cause such differences
include, but are not limited to, risks associated with COVID-19
nationally and globally which could have a material adverse impact
on Aphria's business including delays in undergoing the EU-GMP
inspections of its cultivation facility in Germany, operations and financial results,
including disruptions in cultivation and processing, supply chains
and sales channels, as well as a deterioration of general economic
conditions including national and/or global recessions and the
response of governments to the COVID-19 pandemic in respect of the
operation of retail stores or pharmacies (as applicable); general
economic conditions; adverse industry events; marketing costs; loss
of markets; future legislative and regulatory developments
involving cannabis or otherwise affecting Aphria's business or its
consumers generally; inability to access sufficient capital from
internal and external sources, and/or inability to access
sufficient capital on favorable terms; the cannabis industry in
Canada or in Germany generally; income tax and regulatory
matters, including delays in the issuance of licenses; the sale and
distribution of vapes; the ability of Aphria to meet its liquidity
requirements to fund ongoing operations; the ability of Aphria to
implement its business strategies; competition; crop failure;
safety of derivative cannabis products; currency and interest rate
fluctuations.
Readers are cautioned that the foregoing list is not exhaustive
and should carefully review the various risks and uncertainties
identified in the Company's filings on SEDAR and EDGAR. Readers are
further cautioned not to place undue reliance on forward-looking
statements as there can be no assurance that the plans, intentions
or expectations upon which they are placed will occur. Such
information, although considered reasonable by management at the
time of preparation, may prove to be incorrect and actual results
may differ materially from those anticipated.
The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
Neither TSX nor its Regulation Services Provider (as that term is
defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aphria-inc-strengthens-leadership-position-in-germany-301223812.html
SOURCE Aphria Inc.
